These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35038987)

  • 21. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality.
    Mühlberger N; Schwarzer R; Lettmeier B; Sroczynski G; Zeuzem S; Siebert U
    BMC Public Health; 2009 Jan; 9():34. PubMed ID: 19161623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Dhersin JS; Yazdanpanah Y
    Hepatology; 2016 Apr; 63(4):1090-101. PubMed ID: 26390137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV.
    Limketkai BN; Mehta SH; Sutcliffe CG; Higgins YM; Torbenson MS; Brinkley SC; Moore RD; Thomas DL; Sulkowski MS
    JAMA; 2012 Jul; 308(4):370-8. PubMed ID: 22820790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
    Tada T; Toyoda H; Kumada T; Kurisu A; Sugiyama A; Akita T; Ohisa M; Aikata H; Miki D; Chayama K; Tanaka J
    J Viral Hepat; 2021 Mar; 28(3):538-547. PubMed ID: 33215790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study.
    Kileng H; Gutteberg T; Goll R; Paulssen EJ
    BMC Infect Dis; 2019 Feb; 19(1):189. PubMed ID: 30808290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiological burden estimates for pathologies with a nonconstant risk: an application to HCV in Italy according to age, Metavir score, and genotype: A systematic review and meta-analysis.
    Mancusi RL; Andreoni M; d'Angela D; Sarrecchia C; Spandonaro F
    Medicine (Baltimore); 2016 Oct; 95(42):e5143. PubMed ID: 27759643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.
    Chen Q; Ayer T; Bethea E; Kanwal F; Wang X; Roberts M; Zhuo Y; Fagiuoli S; Petersen J; Chhatwal J
    BMJ Open; 2019 Jun; 9(6):e026726. PubMed ID: 31189677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
    Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
    World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
    Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening strategy to advance HCV elimination in Italy: a cost-consequence analysis.
    Marcellusi A; Mennini FS; Andreoni M; Kondili LA;
    Eur J Health Econ; 2024 Sep; 25(7):1261-1273. PubMed ID: 38280068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis.
    Thein HH; Yi Q; Dore GJ; Krahn MD
    AIDS; 2008 Oct; 22(15):1979-91. PubMed ID: 18784461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China.
    Liu Y; Zhang H; Zhang L; Zou X; Ling L
    Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
    Cousien A; Leclerc P; Morissette C; Bruneau J; Roy É; Tran VC; Yazdanpanah Y; Cox J
    BMC Infect Dis; 2017 Feb; 17(1):162. PubMed ID: 28222681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Country-Wide HCV Elimination Strategies Need to Reach Older Patients in the General Population: The Italian Experience.
    Torre P; Coppola R; Masarone M; Persico M
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
    Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
    HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update.
    Erman A; Krahn MD; Hansen T; Wong J; Bielecki JM; Feld JJ; Wong WWL; Grootendorst P; Thein HH
    BMJ Open; 2019 Nov; 9(11):e027491. PubMed ID: 31719068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men.
    Zahnd C; Salazar-Vizcaya L; Dufour JF; Müllhaupt B; Wandeler G; Kouyos R; Estill J; Bertisch B; Rauch A; Keiser O; ;
    J Hepatol; 2016 Jul; 65(1):26-32. PubMed ID: 26921687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.